KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

被引：0
|
作者：
Cappuzzo, F. [1 ]
Castro Junior, G. [2 ]
Kang, J. H. [3 ]
Wu, Y. L. [4 ]
Brustugun, O. T. [5 ,6 ]
Cheema, P. K. [7 ]
Owonikoko, T. K. [8 ]
Longin, A. S. [9 ]
Duan, J. [10 ]
Caparica, R. [11 ]
Loong, H. H. F. [12 ]
Chan, E. [10 ]
机构：
[1] AUSL Romagna, Hematol Dept, Ravenna, Italy
[2] Univ Sao Paulo, Sao Paulo, SP, Brazil
[3] Catholic Univ Korea, Dept Internal Med, Seoul, South Korea
[4] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[5] Vestre Viken HF, Dramen Hosp, Sect Oncol, Drammen, Norway
[6] Univ Oslo, Fac Med, Oslo, Norway
[7] William Osler Hlth Syst, Brampton, ON, Canada
[8] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[9] Novartis Pharmaceut, Paris, France
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharmaceut, Basel, Switzerland
[12] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2013
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 27 条
  • [21] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [22] A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)
    Gandara, David
    Marrone, Kristen
    Govindan, Ramaswamy
    Skoulidis, Ferdinandos
    Durm, Gregory
    Clarke, Jeffrey
    Frank, Richard
    Krauss, John
    Snyder, Wendy
    Dai, Tian
    Mather, Omar
    Cifuentes, Paul
    Hindoyan, Antreas
    Anderson, Abraham
    Burns, Timothy
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [23] Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
    Zhou, Qing
    Meng, Xiangjiao
    Sun, Longhua
    Huang, Dingzhi
    Yang, Nong
    Yu, Yan
    Zhao, Mingfang
    Zhuang, Wu
    Guo, Renhua
    Hu, Yi
    Pan, Yueyin
    Shan, Jinlu
    Sun, Meili
    Yuan, Ying
    Fan, Yun
    Huang, Jianan
    Liu, Lian
    Chu, Qian
    Wang, Xiuwen
    Xu, Chongrui
    Lin, Jiaxin
    Huang, Jingjing
    Huang, Mengna
    Sun, Jiya
    Zhang, Sujie
    Zhou, Hui
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) : 1630 - 1639
  • [24] Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).
    Fakih, Marwan
    Durm, Greg Andrew
    Govindan, Ramaswamy
    Falchook, Gerald Steven
    Soman, Neelesh
    Henary, Haby Adel
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA9016 - LBA9016
  • [26] Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
    Dingemans, Anne-Marie C.
    Syrigos, Konstantinos
    Livi, Lorenzo
    Paulus, Astrid
    Kim, Sang-We
    Chen, Yuanbin
    Felip, Enriqueta
    Griesinger, Frank
    Ohashi, Kadoaki
    Zalcman, Gerard
    Hughes, Brett Gordon Maxwell
    Sorensen, Jens Benn
    Blais, Normand
    Ferreira, Carlos G. M.
    Lindsay, Colin R.
    Dziadziuszko, Rafal
    Ward, Patrick J.
    Obiozor, Cynthia Chinedu
    Wang, Yang
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [27] Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
    Zhou, Q.
    Meng, X.
    Sun, L.
    Huang, D.
    Yang, N.
    Yu, Y.
    Zhao, M.
    Zhuang, W.
    Hu, Y.
    Pan, Y.
    Sun, M.
    Shan, J.
    Guo, R-H.
    Chu, Q.
    Xu, C.
    Lin, J.
    Huang, J.
    Huang, M.
    Shen, Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1662
123